#1 Clinical Trials Search in Europe

Moxifloxacin

This article examines the use of moxifloxacin, a broad-spectrum antibiotic, in various clinical trials. These studies investigate moxifloxacin’s effectiveness, safety profile, and pharmacokinetics in different formulations and patient populations, including children and those with eye conditions. The research aims to optimize dosing strategies and evaluate potential applications of moxifloxacin in treating infections and ocular disorders.

Table of Contents

What is Moxifloxacin?

Moxifloxacin is a powerful antibiotic medication that belongs to a class of drugs called fluoroquinolones. It is known by various brand names, including Avelox, Vigamox, and BAY12-8039[1][2]. This medication works by killing bacteria or preventing their growth, making it effective against a wide range of infections.

Uses of Moxifloxacin

Moxifloxacin is used to treat various bacterial infections in different parts of the body. Some of its common uses include:

  • Periodontal (gum) infections: It can be used as a treatment for chronic periodontitis, a severe gum infection that can damage the soft tissue and bone that support your teeth[1].
  • Eye infections: Moxifloxacin is effective in treating bacterial conjunctivitis, also known as pink eye. It’s also used to prevent endophthalmitis, a serious eye infection that can occur after eye injuries or surgeries[3][4].
  • Respiratory infections: While not explicitly mentioned in the provided trials, moxifloxacin is known to be effective against various respiratory tract infections.
  • Other bacterial infections: The drug has shown effectiveness against a wide range of bacteria, including those that are resistant to other antibiotics[1].

Administration Methods

Moxifloxacin can be administered in several ways, depending on the type and location of the infection:

  • Oral tablets: For systemic infections, moxifloxacin is often given as oral tablets[5].
  • Intravenous (IV) infusion: In some cases, especially for more severe infections or in hospital settings, moxifloxacin can be given as an IV infusion directly into the bloodstream[2].
  • Eye drops: For eye infections like bacterial conjunctivitis, moxifloxacin is available as an eye drop solution (e.g., Vigamox)[6][4].
  • Topical gel: For periodontal infections, moxifloxacin can be applied directly to the gums as an in situ gel[1].

Effectiveness

Moxifloxacin has shown high effectiveness against various bacterial infections:

  • Periodontal infections: When used as an adjunct to scaling and root planing (a deep cleaning procedure for teeth), moxifloxacin has shown superior outcomes compared to other treatments[1].
  • Eye infections: Moxifloxacin eye drops have been effective in treating bacterial conjunctivitis and preventing post-surgical eye infections[3][4].
  • Wide spectrum of activity: Moxifloxacin is effective against many types of bacteria, including some that are resistant to other antibiotics[1].

Safety and Side Effects

While moxifloxacin is generally considered safe when used as directed, it can cause side effects and requires careful monitoring:

  • Blood glucose effects: Some studies have investigated the potential effects of moxifloxacin on blood glucose levels. While the results are not conclusive, patients with diabetes should be monitored closely when using this medication[5].
  • ECG changes: Moxifloxacin can potentially affect heart rhythm, which is why ECG (electrocardiogram) monitoring is sometimes recommended during treatment[5][7].
  • Joint-related side effects: In some cases, fluoroquinolones like moxifloxacin have been associated with joint-related side effects. This is particularly important in pediatric patients[2].
  • Other side effects: As with any medication, moxifloxacin can cause various side effects. Always discuss potential side effects with your healthcare provider.

Special Considerations

There are some special considerations to keep in mind when using moxifloxacin:

  • Pediatric use: The use of moxifloxacin in children is being studied to determine appropriate dosing and safety[2]. It’s important to note that fluoroquinolones are generally used cautiously in children due to potential effects on developing joints.
  • Antibiotic resistance: Like all antibiotics, the overuse or misuse of moxifloxacin can lead to antibiotic resistance. It’s crucial to use this medication only as prescribed by your healthcare provider[4].
  • Pregnancy and breastfeeding: The safety of moxifloxacin during pregnancy and breastfeeding should be discussed with a healthcare provider.

Remember, moxifloxacin is a prescription medication and should only be used under the guidance of a healthcare professional. Always follow your doctor’s instructions and complete the full course of treatment, even if you start feeling better before it’s finished.

Aspect Details
Drug Formulations Oral tablets, intravenous infusions, eye drops (Vigamox)
Patient Populations Adults, children (3 months to 14 years), patients with eye conditions
Key Study Objectives Pharmacokinetics, safety, efficacy in various conditions
Main Pharmacokinetic Measures AUC, Cmax, tmax, half-life, clearance, volume of distribution
Safety Assessments Joint examinations (pediatric), ocular health, general tolerability
Ocular Applications Bacterial conjunctivitis, ocular graft-versus-host disease
Comparison Studies Placebo-controlled, different dosing regimens
Outcome Measures Bacterial cultures, symptom relief, visual acuity, ocular surface health

FAQ

  • What is moxifloxacin used for in clinical trials? Moxifloxacin is being studied for various uses, including treating bacterial infections, ocular conditions like bacterial conjunctivitis, and potential applications in ocular graft-versus-host disease. Trials are exploring its effectiveness in different formulations such as oral tablets, intravenous infusions, and eye drops.
  • Are there studies on moxifloxacin use in children? Yes, there are clinical trials investigating the safety, tolerability, and pharmacokinetics of moxifloxacin in pediatric patients. These studies aim to determine appropriate dosing strategies for children of different age groups, ranging from 3 months to 14 years old.
  • What are some of the side effects being monitored in moxifloxacin trials? Researchers are monitoring various side effects, with particular attention to joint-related issues in pediatric studies. In ocular studies, effects on the eye surface, visual acuity, and overall ocular comfort are being assessed. General safety and tolerability are evaluated across all trials.
  • How is moxifloxacin being studied for eye conditions? Moxifloxacin is being investigated as an eye drop formulation (Vigamox) for conditions like bacterial conjunctivitis and ocular graft-versus-host disease. Studies are examining its effects on bacterial cultures, ocular surface health, and symptom relief compared to placebos or other treatments.
  • What pharmacokinetic aspects of moxifloxacin are being studied? Clinical trials are examining various pharmacokinetic parameters of moxifloxacin, including its absorption, distribution, and elimination from the body. Specific measures include area under the concentration-time curve (AUC), maximum plasma concentration (Cmax), time to reach maximum concentration (tmax), and half-life (t1/2).

Ongoing Clinical Trials on Moxifloxacin

  • Study of Switching from Intravenous to Oral Antibiotics in Patients with Infective Endocarditis Using a Drug Combination

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on the Effectiveness of Clarithromycin and Other Drug Combinations for Patients with Uncomplicated Staphylococcus aureus Blood Infection

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Continuous vs. Intermittent Infusion of Ampicillin and Ceftriaxone for Patients with Enterococcus faecalis Infective Endocarditis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Croatia Czechia Estonia France Germany +7

  • Study on the Effectiveness of Moxifloxacin and Drug Combination for Treating Bone Implant Infections in Patients with Long Bone Fractures

    Recruiting

    3 1 1 1
    Investigated drugs:
    Spain

  • Study on Early Oral Antibiotic Treatment for Vertebral Osteomyelitis Using Cefuroxime, Dicloxacillin, and Ceftriaxone for Adult Patients

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study of Aztreonam-Avibactam and Metronidazole for Children with Serious Gram-Negative Bacterial Infections

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Greece Hungary Spain

  • Study on the Effects of Rifampicin, Amoxicillin, and Moxifloxacin in Treating Prosthetic Joint Infections Caused by Cutibacterium acnes for Affected Patients

    Recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness of Clofazimine and Drug Combination for Treating Mycobacterium abscessus Lung Disease in Adult Patients

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on the Effectiveness of Ceftriaxone and Metronidazole Combination for Patients with Hurley Stage 2 Hidradenitis Suppurativa

    Recruiting

    3 1 1
    Investigated drugs:
    France

Glossary

  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time. This includes measures like AUC, Cmax, and half-life.
  • AUC (Area Under the Curve): A measure of the total exposure to a drug over time, calculated from the concentration-time curve. It helps determine the overall amount of drug in the body.
  • Cmax: The maximum (or peak) concentration of a drug observed in the blood plasma after administration.
  • Half-life (t1/2): The time it takes for the concentration of a drug in the body to decrease by half. It helps determine how often a drug needs to be administered.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Ocular graft-versus-host disease: An eye complication that can occur after a stem cell or bone marrow transplant, where the donor's immune cells attack the recipient's eye tissues.
  • Bacterial conjunctivitis: An infection of the eye's conjunctiva (the clear membrane covering the white part of the eye) caused by bacteria, often treated with antibiotic eye drops.
  • Visual Analog Scale (VAS): A measurement tool used to assess subjective characteristics or attitudes that cannot be directly measured, often used for pain or discomfort assessment.
  • Placebo: A substance with no active therapeutic effect, used as a control in clinical trials to test the effectiveness of a drug.
  • Intravenous (IV) infusion: The administration of a drug directly into a vein over a period of time.

References

  1. https://clinicaltrials.gov/study/NCT02016157
  2. https://clinicaltrials.gov/study/NCT01049022
  3. https://clinicaltrials.gov/study/NCT05079854
  4. https://clinicaltrials.gov/study/NCT00312338
  5. https://clinicaltrials.gov/study/NCT04692623
  6. https://clinicaltrials.gov/study/NCT00690313
  7. https://clinicaltrials.gov/study/NCT03162900